For the full year of 2024, the Company expects: Total revenue between $53.0 million and $57.0 million; gross margin between 83% and 84%; Operating expenses between $86.0 million and $90.0 million.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CVRX:
- CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results and Announces Nadim Yared Retirement Plans
- CVRx to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- CVRx price target raised to $32 from $21 at Lake Street
- Barostim’s label upgrade caps off successful 2023 for CVRx, says Craig-Hallum
- CVRx receives FDA approval for expanded labeling of Barostim
